Universität zu Köln

Schneider, Christian, Wunderlich, Gilbert, Bleistein, Johannes, Fink, Gereon R. ORCID: 0000-0002-8230-1856, Deckert, Martina, Brunn, Anna and Lehmann, Helmar Christoph (2017). Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy. J. Neurol. Neurosurg. Psychiatry, 88 (9). S. 756 - 761. LONDON: BMJ PUBLISHING GROUP. ISSN 1468-330X

Full text not available from this repository.

Abstract

Objective To identify the most relevant antigens for monoclonal antibodies in lymphocytic infiltrates in non-systemic vasculitic neuropathy (NSVN). Background Current immunosuppressive treatment for NSVN is insufficient. Monoclonal antibodies might be a treatment option, but the expression profile for targetable antigens on lymphocytic infiltrates in NSVN is unknown. Methods Sural nerve biopsies from a cohort of patients with NSVN were immunohistochemically studied for the expression of potential candidate antigens in perivascular and intramural lymphocytic infiltrates and correlated with neurological and electrophysiological parameters. 20 patients with treatment naive NSVN and 5 patients with idiopathic axonal neuropathy were included. Results The CD52, BAFF and CD49d antigens were expressed in epineurial, perivascular or intramural lymphocytes of all (20/20) patients. CD52 was most prominently expressed in 21.49% of all inflammatory infiltrates. BAFF and CD49d were detected in 11.25% and 10.99% of these lymphocytes, respectively. The CD20, CD25 and CD126 antigens were found less frequently and at low levels only (CD20: 10/20 patients, 5.84% of lymphocytes; CD25: 17/20 patients, 5.22% of lymphocytes; CD126: 3/20 patients, 0.15% of lymphocytes). Conclusion This is the first study in NSVN that identifies antigens expressed by pathogenic lymphocytes, which are potential targets for future monoclonal antibody treatment. Our data suggest that NSVN is amenable to monoclonal antibodies and, moreover, that targeting CD52 may be particularly promising. Our results strongly warrant future clinical trials in NSVN with monoclonal antibodies.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schneider, Christian UNSPECIFIED UNSPECIFIED UNSPECIFIED Wunderlich, Gilbert UNSPECIFIED UNSPECIFIED UNSPECIFIED Bleistein, Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Fink, Gereon R. UNSPECIFIED orcid.org/0000-0002-8230-1856 UNSPECIFIED Deckert, Martina UNSPECIFIED UNSPECIFIED UNSPECIFIED Brunn, Anna UNSPECIFIED UNSPECIFIED UNSPECIFIED Lehmann, Helmar Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-220932
DOI:	10.1136/jnnp-2017-315878
Journal or Publication Title:	J. Neurol. Neurosurg. Psychiatry
Volume:	88
Number:	9
Page Range:	S. 756 - 761
Date:	2017
Publisher:	BMJ PUBLISHING GROUP
Place of Publication:	LONDON
ISSN:	1468-330X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INFLAMMATORY DEMYELINATING POLYNEUROPATHY; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RELAPSING MULTIPLE-SCLEROSIS; DISEASE-MODIFYING THERAPY; CONTROLLED PHASE-3 TRIAL; FOLLOW-UP; ALEMTUZUMAB; NATALIZUMAB; MAINTENANCE; STIMULATOR Multiple languages Clinical Neurology; Psychiatry; Surgery Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/22093